BioNTech is making moves in early 2024 to strengthen its CAR T pipeline, with a $250 million licensing and manufacturing deal announced Thursday with Autolus Therapeutics to advance the companies’ respective programs.
Tag Archive for: licensing agreement
Under the terms of the deal, Lilly will make an upfront payment and pledges up to $660 million in preclinical, clinical and commercial development milestones. The Japanese biotech will also be eligible for royalties on future sales of any pharmaceutical product that emerges from the partnership.
While a particular target was not disclosed, PeptiDream CEO Patrick Reid said in a statement that the company hopes to “bring innovative first-in-class peptide radiopharmaceuticals to patients worldwide.”
A week after licensing a novel gene therapy from Kate Therapeutics to treat X-linked myotubular myopathy, Astellas Wednesday announced a strategic collaboration with San Diego- and China-based Cullgen to develop multiple targeted protein degraders.
AstraZeneca inked a non-exclusive licensing agreement with Revvity for access to the Massachusetts biotech’s proprietary gene editing technology to develop cell therapies for cancer and immune-mediated conditions, Revvity announced Thursday.
The company has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.
Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.
Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.
Biotech behemoth Amgen inked a licensing agreement Thursday with Netherlands-based Synaffix for the development of next-generation antibody-drug conjugates.
Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer.
